Affimed Therapeutics B.V. - AFMD

Ich bleibe erstmal weiter an der Seitenlinie. Aktuell bekommt man einige interessante Biotechs zum Cashwert, da muss ich hier noch nicht ins kalte Wasser springen, solang sich die Bewertung nicht an den Cashwert annähert.  MK 388 Mio. $ (369 Mio. €) bei ~270 Mio. € Cash. Setze mir einen Alert auf 2,10$.  

haste welche bekommen?

könnte mir vorstellen wir haben die tiefs gesehen. that said, konnte mir nicht vorstellen wie tief die tiefs gehen!:-)

freu mich auf das zweite halbjahr. es stehen einfach viele news aus, von denen die meisten positiv s und den afmd bull case unterfüttern sollten.

ich hab jedenfalls büschen verbilligt.  

Affimed: Preparing For Key Inflection Points

https://seekingalpha.com/article/...eparing-for-key-inflection-points  

ist von dem ind rückzug für afm28 zu halten?  

Affimed hat nach Rückmeldungen der FDA eine strategische Entscheidung getroffen:
AFM28 (CD123/CD16A) IND freiwillig zurückzuziehen.
Es gibt Pläne, die klinische Entwicklung von AFM28 in Gerichtsbarkeiten außerhalb der USA voranzutreiben.
https://www.fiercebiotech.com/biotech/...ispecifics-first-human-study  

was die FDA zu bemängeln hatte - in Europa könnte es einfacher sein, eine entsprechende Patientengruppe zu finden und mit einer gesicherten Dosierung die US Regulierungsbehörde dann für das Thema zu begeistern.  

 

Affimed: Ein wirksamer Ansatz zur Behandlung von Blutkrebs

Affimed ist ein deutsches Biotech-Unternehmen, das eine neuartige Plattform von "innate cell engagers", d.h. Antikörpern, die natürliche Killerzellen und Tumore miteinander verbinden, zur Behandlung verschiedener Blutkrebsarten entwickelt. Bislang hat das Unternehmen sehr überzeugende Daten für rezidivierende/refraktäre CD30-positive Lymphome sowie für rezidivierende/refraktäre periphere T-Zell-Lymphome vorgelegt.

Kürzlich musste Affimed einen kleinen Rückschlag hinnehmen, nachdem Diskussionen mit der Food and Drug Administration (FDA) das Unternehmen dazu veranlassten, sein erstes klinisches Programm in den USA für AFM28, einen experimentellen Kandidaten für akute myeloische Leukämie, zurückzuziehen. Das Unternehmen sagte, dass es plant, dieses Programm wieder aufzunehmen, sobald es zusätzliche Daten für AFM28 aus anderen klinischen Zentren in den USA hat.

Trotz des stetigen Fortschritts von Affimed in der Klinik ist die Aktie des Biotech-Unternehmens im Jahresverlauf um fast 50 % gefallen. Kurz gesagt, die Wall Street hat in diesem Jahr keine Geduld für Biotech-Unternehmen im Versuchsstadium gezeigt, und die Aktie von Affimed hat darunter gelitten. Erfahrene Anleger sollten jedoch in die Fußstapfen von Baker Bros. treten. Der führende Produktkandidat von Affimed, AFM13, könnte bei der Zulassung mehrere hundert Millionen Umsatz generieren - und die bisherigen Daten scheinen bahnbrechend zu sein.

Übersetzt mit www.DeepL.com/Translator (kostenlose Version)

https://www.nasdaq.com/articles/...these-3-beaten-down-biotech-stocks  

 

Zahlen für Q2/22

• Umsatz 7,3 Mio. €
  
• Verlust 19,4 Mio. €
  
• Cash 237 Mio. €
  
• MK 293 Mio. $
  

- anticipated cash runway into mid-2024

https://www.affimed.com/...nd-highlights-recent-operational-progress/

 

Stifel veröffentlichte einen 72-seitigen Short Report mit dem Kursziel von 2$.
https://twitter.com/JamesFr6_8/status/1579437267671977986/photo/1  

sehen wir hier bald den nächsten Pennystock.  

über Affimed und NK-Zelltherapien lesen (auf Englisch aber aus Berlin und ein ex-Medigene CMO)

Kai Pinkernell, chief medical officer at Glycostem, discusses how natural killer (NK) cell therapies could usher in off-the-shelf cancer immunotherapies.

 

https://seekingalpha.com/article/..._alpha&utm_term=29494161.2148
 

Pieris Pharmaceuticals Reports Third Quarter 2022 Financial Results and Provides Corporate Update
COMPANY TO HOST AN INVESTOR CONFERENCE CALL ON WEDNESDAY, NOVEMBER 2, 2022 AT 8:00 AM EDT

Elarekibep (PRS-060/AZD1402) phase 2a study for asthma enrollment continues
First subject dosed in PRS-220 phase 1 study for idiopathic pulmonary fibrosis (IPF)
PRS-344/S095012 phase 1 study for solid tumors in collaboration with Servier continues
IND accepted for SGN-BB228 (also known as PRS-346) phase 1 immuno-oncology study; preclinical data to be presented at SITC 2022
PRS-342/BOS-342 phase 1 for solid tumors expected to begin in the next six months
PRS-400 preclinical data for muco-obstructive diseases presented at ERS

BOSTON, MA / ACCESSWIRE / November 2, 2022 / Pieris Pharmaceuticals, Inc. (NASDAQ:PIRS), a clinical-stage biotechnology company advancing novel biotherapeutics through its proprietary Anticalin® technology platform for respiratory diseases, cancer, and other indications, reported financial results for the third quarter of 2022 ended September 30, 2022, and provided an update on the Company's recent and anticipated future developments.

"Today's update highlights the value of our partnerships, which are validating our science, advancing and replenishing our clinical-stage pipeline, and satisfying a significant amount of our funding needs. AstraZeneca continues to advance our lead inhaled respiratory asset, elarekibep, while we continue to advance our lead IO bispecific program, PRS-344/S095012, in co-development with Servier. Furthermore, we are excited that Seagen and Boston Pharmaceuticals will soon initiate clinical development for their respective IO bispecifics programs, SGN-BB228 and PRS-342/BOS-342, which use Pieris' platform technology. This clinical progress follows the recent phase 1 initiation of our fully proprietary inhaled respiratory program, PRS-220," said Stephen S. Yoder, President and CEO of Pieris. "We will continue to make disciplined pipeline investments that demonstrate our commitment to achieve inflection points in the next year within our partnered and proprietary programs."

Elarekibep and AstraZeneca Collaboration: AstraZeneca has completed enrollment of part 1b (safety of 10 mg cohort) and continues to enroll part 2 (efficacy of 3 mg cohort) of the multi-center, placebo-controlled phase 2a study of dry powder inhaler-formulated elarekibep (PRS-060/AZD1402), an IL-4 receptor alpha inhibitor Pieris is developing with AstraZeneca for the treatment of moderate-to-severe asthma. AstraZeneca has completed all submissions of the previously announced protocol amendments to improve enrollment. Topline results, which will include FEV1 improvement of the 3 mg cohort versus placebo, are expected to be reported by the third quarter of 2023. Upon delivery of these results, Pieris may choose to exercise its co-development option. Separately, Pieris will have a future option to co-commercialize elarekibep in the United States. Beyond elarekibep, Pieris continues to work on two discovery-stage programs with AstraZeneca, for which the research term was recently extended. Pieris retains co-development and U.S. co-commercialization options for these two programs.

PRS-344/S095012 and Servier Collaboration: Pieris and Servier continue to enroll the escalation portion of the phase 1/2 study of PRS-344/S095012, a 4-1BB/PD-L1 bispecific MabcalinTM (antibody-Anticalin fusion) compound for the treatment of solid tumors, for which Pieris holds full U.S. rights and will receive royalties on ex-U.S. sales by Servier. The companies expect to present data from the study at a medical meeting in 2023. Additionally, Servier is continuing development of PRS-352/S095025, an OX40/PD-L1 bispecific Mabcalin compound.

PRS-220: Pieris has dosed the first subject in the phase 1 study in healthy volunteers of PRS-220, a proprietary inhaled Anticalin protein targeting connective tissue growth factor (CTGF) for the treatment of IPF and other forms of fibrotic lung disease. The Company expects to report the outcome from the study in 2023. PRS-220 continues to benefit from a meaningful grant from the Bavarian government, which supports early-stage clinical development of this program.

Seagen Collaboration: The investigational new drug (IND) application for the phase 1 study of SGN-BB228 (also known as PRS-346), a first-in-class 4-1BB/CD228 bispecific Mabcalin compound, has been accepted. Seagen plans to initiate a phase 1 study for SGN-BB228 in the coming months, for which Pieris will receive a milestone payment. Seagen will also present preclinical data for the program at a poster session during the Society for Immunotherapy of Cancer 37th Annual Meeting. Seagen continues to develop a second undisclosed bispecific program under the companies' immuno-oncology collaboration. Pieris has a multi-asset collaboration with Seagen and has an opt-in option to a U.S. co-promotion for one program in the collaboration.

PRS-342/BOS-342: Boston Pharmaceuticals continues to advance PRS-342/BOS-342, a 4-1BB/GPC3 bispecific Mabcalin compound, towards the clinic, with phase 1 expected to begin in the next six months.

PRS-400: Pieris unveiled and presented preclinical data for PRS-400, an inhaled Jagged-1 Anticalin protein the Company is developing for the treatment of muco-obstructive lung diseases, at the European Respiratory Society (ERS) International Congress 2022.
Second Quarter Financial Update:

Cash Position - Cash, cash equivalents, and investments totaled $69.8 million for the quarter ended September 30, 2022, compared to a cash and cash equivalents balance of $117.8 million for the year ended December 31, 2021. The decrease is due to funding operations in 2022. Including the proceeds from anticipated near-term milestones, the Company believes operations are sufficiently funded into the second quarter of 2024.

R&D Expense - R&D expenses were $13.6 million for the quarter ended September 30, 2022, compared to $18.9 million for the quarter ended September 30, 2021. The decrease is due to lower program costs, as work related to the Company's sponsored phase 1 trial of elarekibep was largely complete in 2021, as well as due to lower manufacturing costs across all later-stage respiratory and immuno-oncology programs, and lower consulting costs. These lower costs were partially offset by higher clinical costs for PRS-344/S095012, higher pre-clinical costs for earlier stage programs, and an increase in personnel costs.

G&A Expense - G&A expenses were $3.9 million for the quarter ended September 30, 2022, compared to $4.1 million for the quarter ended September 30, 2021. The period-over-period decrease was driven primarily by lower personnel and legal costs, partially offset by higher professional services and travel costs.

Other Income - For the quarter ended September 30, 2022, $1.5 million of grant income was recorded with respect to PRS-220, compared to $1.8 million for the quarter ended September 30, 2021. The decrease is due to lower overall costs incurred this quarter on PRS-220.

Net Loss - Net loss was $9.7 million or $(0.13) per share for the quarter ended September 30, 2022, compared to a net loss of $16.5 million or $(0.24) per share for the quarter ended September 30, 2021.  

Forum gelandet - das sollte zu Pieris :-(  

sich selbst auf der Jefferies London Healthcare Conference
Dr. Adi Hoess, CEO am 16-ten November 16, 2022
um 13:55 CET (mit WebCast)

 

 

Konferenz um 15:30 Uhr  

deal according to Endpoints.  

 

 

Meines Erachtens haben wir gestern und vorgestern den Ausbruch aus dem lfr Abwärtstrend geschafft  

M.E.n. noch nicht

 

...ich habe nicht den logarithmischen Chart genommen. Ich meine mich erinnern zu können, dass wir diese Diskussion schon mal hatten :)